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http:WHAT THIS PAPER ADDS
This paper reviews renal physiology and highlights the methodological challenges and limitations for studies of
renal artery stenosis.Objectives: To assess the literature on intervention for renal artery stenosis (RAS), with special emphasis on the
last two and largest randomized trials, the ASTRAL and CORAL trials.
Design: A review of renal physiology, pathology, and pathophysiology of RAS and a critical analysis of the
randomized trials.
Materials: Published literature for renal physiology and RAS were assessed.
Methods: Renal physiology, renal intervention, and the limitations and challenges of both ASTRAL and CORAL are
analysed.
Results: The last two reported, and largest randomized trials of percutaneous renal artery intervention for RAS
were the ASTRAL and the CORAL trials; both generated much debate and much controversy, however both trials
had methodological shortcomings, and assumed a simplistic approach to renal physiology. Both trials were
hampered by slow recruitment, and there were protocol changes to accommodate, and CORAL was not powered
for subgroup analysis. The primary outcome measure for ASTRAL was the reciprocal of serum creatinine levels
and CORAL a complex composite endpoint of cardiovascular or renal events. In ASTRAL, 25% of patients had
normal renal function and 40% almost normal renal function; and in CORAL, 50% of the cohort had either no
renal failure, or were Stage I or Stage II CKD, (i.e. eGFR of >60 mls/min/1.73 m2). In ASTRAL, 41% of patients had
a stenosis of <70%; and an interim analysis of 611 patients (of 947 enrolled) in CORAL revealed that 55% had
<70% renal artery stenosis.
Conclusions: Best evidence still supports intervention for patients with RAS of >80% with a signiﬁcant trans-
lesional pressure gradient; difﬁcult to control blood pressure with more than three antihypertensives, especially
in younger patients; and those with truncal rather than ostial stenosis; patient with a rapid deterioration of renal
function; ﬂash pulmonary oedema; and post-transplant RAS.
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Renal artery stenosis (RAS) is associated with compromised
renal perfusion, hypertension, ischaemic nephropathy, and
end-stage renal failure, and also some other long-term
complications of atherosclerotic disease. The majority ofrresponding author. I.V. Mohan, Norwest Vascular Specialists, Suite
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//dx.doi.org/10.1016/j.ejvs.2014.12.026cases are due to atherosclerotic renal artery (RA) disease,
and ﬁbromuscular dysplasia (FMD) in about 10% of cases,
and other less common pathology, and the disease may be
bilateral in up to one-third of cases. The management op-
tions for RAS include conservative therapy, medical therapy,
angioplasty or angioplasty and stent, or bypass surgery. The
last two reported, and largest, randomized trials of percu-
taneous renal artery intervention for stenotic renal artery
disease were the ASTRAL and the CORAL trials; both
generated much debate and much controversy.1,2 However,
as discussed in this paper, both trials had methodological
shortcomings, and assumed a simplistic approach to renal
466 I.V. Mohan and V. Bourkephysiology, and concluded that renal artery intervention
offered no advantage to patients with RAS.
Much modern thinking about renovascular disease is still
deeply inﬂuenced by Henry Goldblatt’s experiment.3 A
similar clinical situation in humans is seen when stenosis
affects the RA with a relatively undamaged vascular tree
(e.g. FMD, non-ostial or truncal stenosis, and transplanted
kidney arterial stenosis).3 Blood vessels to the kidney
deliver more oxygenated blood than needed for basal
metabolic demands and the metabolic requirements of the
kidney are achieved with around 10% of normal blood
ﬂow.4,5 A “critical stenosis” causes a reduction in renal
perfusion pressure and occurs when the RA is narrowed by
over 70e80%.6,7 Deterioration of renal function (RF) with
RAS may be the result of sustained hemodynamic insults, or
other ﬁbrogenic processes independent of hemodynamic
changes.8 Ostial stenosis reﬂects generalized atherosclerosis
causing kidney damage, that is hypertensive damage,
spontaneous cholesterol atheroembolism, and may account
for low rate of RF recovery after revascularization. RAS of
greater than 70e80% is also necessary to activate the
intrarenal renineangiotensin system (IRAS) and this degree
of stenosis correlates with a translesional peak systolic
pressure gradient (PG) of 15e25 mmHg.6,7 Relative under-
perfusion in the presence of RAS may result in a medullary
oxygen deﬁciency and may further stimulate the activation
of IRAS that may then activate ischaemia and renal damage,
in a progressively negative cycle.8 Activation of IRAS also
induces renal inﬂammation, cytokine activation, and
oxidative stress and renal damage, including intrarenal
ﬁbrosis and scarring.9e11
Evaluating renal injury related to RAS, must consider that
kidneys are bilateral in most patients, and vascular disease
rarely affects both kidneys and all renal arteries to the same
extent. In the presence of unilateral RA disease the
contralateral kidney is capable of compensatory change,
and contralateral renal hypertrophy may obscure change in
the functional result of both kidneys and may cancel out
changes induced by the stenotic kidney.11
RA disease is linked to the increasing systemic athero-
sclerosis in the ageing population.12,13 Increased prevalence
of ostial lesions is associated with aortic atherosclerotic
disease and thrombus formation that may have already
injured end-organs from progressive atheroembolization.12
An inverse relationship exists between age of patients and
cure of hypertension after revascularization, and also a
positive correlation between age and the rate of worsening
of RF after revascularization.13e15
Patients with more renal tissue at risk are more likely to
have a response or improvement with primary renal inter-
vention for RAS, including those with severe bilateral disease
and with a solitary kidney. Patients with small kidneys
(<7 cm) and those with signiﬁcant proteinuria are less likely
to beneﬁt. But there is signiﬁcant support for intervention
and revascularization of unilateral RAS to improve RF but
successful revascularization is dependent on the adequacy of
relief of the RAS, the remaining viable functional renal tissue,
and the safety of the revascularization procedure.13,14Recovery of RF after revascularization is different with
ostial stenosis compared with “true” RAS (non-ostial or
truncal lesions); signiﬁcant improvement of RF in 44.5e77%
of cases with truncal stenosis, FMD, and post-transplant
stenosis. However with well-documented ostial stenosis,
improvement was seen in only about 20% of patients.13,14
Improvement in RF after successful stent placement for
RAS is only seen in around 25%, with RF remaining stable in
50%, and deteriorating in 25%.13,14 The reason for this may
be due to clinically evident acute atheroembolic renal dis-
ease, which is associated with a dramatically negative effect
on prognosis. Although the majority of atheroembolic renal
disease is subclinical the reported frequency of visible
atherosclerotic debris recovered in protection devices is
well above 50%, and perhaps this atheroembolization
associated with the 25% of successfully revascularized kid-
neys showing a decline in RF.15e17
Evidence from randomized trials
Older renal artery trials, for example STAR (Stent Placement
in Patients With Atherosclerotic Renal Artery Stenosis and
Impaired Renal Function) trial and the DRASTIC (Dutch
Renal Artery Stenosis Intervention Cooperative) trial, were
underpowered and seriously ﬂawed.18 And the RADAR trial,
(A randomised, multi-centre, prospective study comparing
best medical treatment versus best medical treatment plus
renal artery stenting in patients with haemodynamically
relevant atherosclerotic renal artery stenosis), was termi-
nated prematurely.19
The last two reported and largest randomized trials of
percutaneous RA intervention for stenotic RA disease were
the ASTRAL (Angioplasty and Stenting for Renal Artery Le-
sions) trial in the UK, and CORAL (Stenting and Medical
Therapy for Atherosclerotic Renal-Artery Stenosis) trial that
was based in the United States.1,2 Both trials generated
much debate and much controversy, but no ﬁnality. A
summary of the main outcome measures for the ASTRAL
and CORAL trial is shown in Table 1.
Neither of these trials demonstrated a beneﬁt of RA
intervention over medical therapy, in contrast to the ﬁnd-
ings of large interventional cohort studies and meta-
analyses. In the ASTRAL study, data were presented for
the more affected kidney for which a surgical plan was
provided at the time of randomization; in CORAL global
ischaemia was deﬁned as stenosis of 60% or more of the
diameter of all arteries supplying both kidneys or stenosis of
60% or more of the diameter of all arteries supplying a
single functioning kidney, and was present in only 20% of
patients in the stenting group and 16.2% of the medical
group; bilateral disease was present in 22% of the stenting
group and 18.1% of the medical arm.
ASTRAL
The starting point for ASTRAL was that the treating physi-
cian had to be guided by an “uncertainty principle”, which
said that the physician had to be undecided or have “clinical
equipoise” that the patient would have a worthwhile
Table 1. Summary of the ASTRAL and CORAL trials, and primary and secondary outcome measures.
Outcome measure ASTRAL1 CORAL2
Primary outcome Renal function.
(Measured by the reciprocal of the serum creatinine level).
The occurrence of a major cardiovascular or renal event.
(Death from cardiovascular or renal causes, stroke,
myocardial infarction, hospitalization for congestive
heart failure, progressive renal insufﬁciency, or
permanent renal-replacement therapy.)
Secondary outcome 1. Blood pressure.
2. Time to renal and major cardiovascular events.
3. Mortality.
1. Death from cardiovascular causes and Death from
renal causes (as separate end points).
2. All-cause mortality.
Follow-up Median 34 months Median 43 months
Renal function Mean serum creatinine level was 1.6 mmol/L (95% conﬁdence interval
[CI], 8.4 to 5.2 [0.02 mg per deciliter; 95% CI, 0.10 to 0.06]) lower in
the revascularization group.
The rate of progression of renal impairment demonstrated a difference,
lower in the revascularization group of 0.06103 liters per micromole
per year (95% CI, 0.002 to 0.13; P ¼ 0.06).
Creatinine (p[0.09)
> 141 mmol/L
Revascularization: 51.2% vs Medical: 39.1%.
 141 mmol/L
Revascularization: 31.8 % vs Medical: 34.9 %
Estimated glomerular ﬁltration rate (p [ 0.80)
‡45 ml/min/1.73 m2
Revascularization: 31.6% vs Medical: 33.8%.
<45 ml/min/1.73 m2
Revascularization: 43.2% vs Medical: 39.9%.
Blood pressure Baseline
Mean systolic/diastolic blood pressure, mmHg (standard deviation).
Revascularization: 149  24/76  12
Medical: 152  25/76  13
Baseline systolic BP mmHg (standard deviation).
Revascularization: 149.9  23.2
Medical: 150.4  23.0
At ﬁve years
Revascularization: 141  26/73  12
Medical: 141  25/70  13
During the 5-year study period, systolic blood and diastolic blood
pressure decreased in both study groups, with no signiﬁcant difference
between the groups.
At three years
Revascularization: 141  26/73  12
Medical: 141  25/70  13
Systolic BP decreased in:
Revascularization: 15.6  25.8
Medical: 16.2  21.2
Systolic blood pressure slightly lower in revascularization
(2.3 mmHg, 95% CI 4.4 to 0.2, p-value ¼ 0.030).
Death All cause mortality
Hazard ratio: 0.90; 95% CI, 0.69 to 1.18; p ¼ 0.46.
Any cause mortality
Hazard ratio: 0.80; 95% CI, 0.58e1.12, p ¼ 0.20.
Death from cardiovascular causes
Hazard ratio: 0.89; 95% CI, 0.58e1.36, p ¼ 0.60.
Death from renal causes
Hazard ratio: 1.89; 95% CI, 0.17e20.85, p ¼ 0.60.
Major cardiovascular events Hazard ratio: 0.94; 95% CI, 0.75 to 1.19; p ¼ 0.61. Hazard ratio: 0.97; 95% CI, 0.67 to 1.40; p ¼ 0.88.
Renal events Hazard ratio: 0.97; 95% CI, 0.67 to 1.40; p ¼ 0.88. Progressive renal insufﬁciency.
Hazard ratio: 0.86; 95% CI, 0.64 to 1.17; p ¼ 0.34
Permanent renal replacement therapy.
Hazard ratio: 1.98; 95% CI, 0.85 to 4.62; p ¼ 0.11
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468 I.V. Mohan and V. Bourkeclinical beneﬁt from revascularization or medical manage-
ment alone. To exclude patients, the treating physicians
were either sure they needed or they did not need renal
revascularization, and this certainly introduced considerable
selection bias into the trial design and allowed entry into
the trial of patients with moderate RAS and with minimal or
no hypertension. In the ASTRAL trial, the primary outcome
measure was the change in RF over time. A total of 806
patients with atherosclerotic RAS were randomized to
either stent-based revascularization combined with medical
therapy or medical therapy alone. The investigators
changed the 700 patients designated for enrolment in a
major protocol departure. The initial target enrolment of
750 patients was increased to 1,000 to allow for crossover
and was then again reduced to 700 when the crossover rate
was reassessed.1
Of 403 patients randomized to receive RA stenting, only
83% actually received an intervention and only 79% were
successful. In fact, 41% of subjects had a stenosis less than
70%. These are the patients who are least likely to beneﬁt
from RA stenting. There was no mandatory RF assessment
and also no mandated protocol for treating hypertension in
the study protocol. There was no mandated arterial follow-
up of the treated arteries by any modality, even with duplex
imaging, and patency rates of treated arteries were not
reported during follow-up. Best medical therapy in the
medical arm was also left to the investigator, and there was
no speciﬁc cholesterol and lipids target, and no speciﬁc
antiplatelet regimen for each groups (see Table 2).
In ASTRAL, about 40% of patients entered had a stenosis
of less than 50%. And some patients in the group with
“stenosis greater than 70%” actually had stenosis of less
than 70%; and the majority of the patients in ASTRAL had
only mild to moderate RAS. In a study designed to assess
changes in RF as its primary outcome measure, 25% of
patients had normal RF and a further 15% almost-normal RF
at baseline, from the outset of the trial. However, and
perhaps not surprisingly the decline in RF was lower than
expected in the medical arm, but the post-procedural
glomerular ﬁltration rate (GFR) and other parameters of
RF were not reported, and around a third of patients in
each arm were lost to follow-up at 2 years.
The major adverse event rate was 9%. One-ﬁfth of the
stented cohort suffered a serious complication including
two deaths, signiﬁcantly higher than that reported in other
renal stenting series, and 20% for less serious complica-
tions. Over 7 years of recruitment, 61% of all 57 partici-
pating hospitals, randomized nine patients or fewer,
including 42% that randomized between one and ﬁve pa-
tients. There was no minimum requirement of pre-trial
experience for a centre to participate, and some centres
randomized, on average, less than one patient per year,
perhaps accounting for the unacceptably high complication
rate, although it is unclear how many patients were being
treated outside the trial in these centres. The major pro-
cedural complication rate (vessel dissection, occlusion,
distal embolization, etc.) was 5.2% in CORAL, not too dis-
similar to ASTRAL.1,2ASTRAL had a large enough sample size, but shortcom-
ings in study design and application of its protocol in-
validates its results for the population of patients with RAS.
Despite these ﬂaws the authors concluded that: “We found
substantial risks but no evidence of a worthwhile clinical
beneﬁt from revascularization in patients with atheroscle-
rotic renovascular disease.”1CORAL
The CORAL study investigated the cardiovascular outcomes
in renal atherosclerotic lesions comparing stent and best
medical therapy to best medical therapy, and aimed to
address some of the methodological shortcomings of other
renal interventional trials but did exclude FMD. The aim of
this trial was to evaluate “hard” clinical endpoints, with
combined primary endpoints of death from cardiovascular or
renal causes, stroke, myocardial infarction, and hospitaliza-
tion for congestive cardiac failure, progressive renal insufﬁ-
ciency, and permanent renal replacement therapy. The
secondary endpoints included individual components of the
primary endpoint. The evaluation committee was blinded
and assessed time to ﬁrst primary endpoint on an intention
to treat basis. Enrolment for this study began in 2005.2
The original protocol included patients with greater than
60% but less than 100% RAS on angiography, with systolic
blood pressure (BP) of greater than 155 mmHg and patients
taking two or more anti-hypertensive medications. If the
RAS was between 60% and 80%, the trial centre needed to
demonstrate a PG of at least 20 mmHg. Enrolment was slow
and there were changes to the original protocol; a threshold
systolic BP of greater than 155 mmHg was no longer
speciﬁed. Patients could be enrolled even in the absence of
systolic hypertension but had to have at least stage IIIA
chronic kidney disease (CKD) with eGFR of less than 60 mL/
min. In addition, severe RAS could be deﬁned using other
modalities including duplex ultrasound velocities >300 cm/
s, magnetic resonance angiography (MRA), or computed
tomography angiography (CTA) as approved by core labo-
ratory analysis, even though angiographic and hemody-
namic measures of lesion severity do not correlate well.20
Leesar and colleagues21 in a large series demonstrated
that the strongest correlation for BP improvement after
intervention for RAS was the hyperaemic translesional PG,
and measurements in 176 patients in CORAL demonstrated
a direct correlation with the degree of RAS.22
And although the exclusion criteria included patients with
CKD from a non-ischaemic cause, a signiﬁcant proportion in
CORAL (311 patients, approximately one-third of each
group) were diabetic, perhaps also with diabetic renal fail-
ure. Both diabetic and non-diabetic patients had different
acceptable target BP, and CORAL did not explicitly identify
how to establish or differentiate hypertension from a
renovascular cause, or in diabetic patients with CKD,
especially after protocol changes. It has also been previ-
ously reported that proteinuria, (common in patients with
diabetes) is a predictor of poor outcome after revasculari-
zation. Therefore, the inclusion of diabetic patients is a
Table 2. Summary of patients, protocols and protocol changes for the ASTRAL and CORAL trials.
ASTRAL1 Original protocol Protocol changes Patients eventually randomized
Revascularization versus Medical Therapy for
Renal Artery Stenosis.
ASTRAL was a multicenter, randomized, un-
blinded clinical trial. Patients were eligible for
inclusion if clinical ﬁndings and imaging studies
conﬁrmed stenosis in at least 1 renal artery.
No Core Laboratory
Non-standardized medical or interventional
therapy
The power analysis designated 700
patients for enrollment with a power of
80% and a two-tailed P value of 0.05, to
detect a reduction of 20% in the mean
slope of the reciprocal of the serum
creatinine level. Initial target
enrollment was 750.
Primary end-point was a loss of renal
function.
Secondary end-points were changes in
blood pressure, time to major renal and
cardiovascular events and mortality.
Uncontrolled or refractory
hypertension OR unexplained renal
dysfunction. Substantial anatomical
atherosclerotic stenosis in at least one
renal artery potentially suitable for
endovascular revascularization.
Patients with Diabetes not excluded.
Target increased to 1,000 to allow for
crossover. Reduced to 700 as
anticipated crossover was less than
anticipated.
Patients thought likely to beneﬁt by
primary physician excluded from trial.
At least one-follow-up visit over 5-years
accepted in ﬁnal analysis.
806 eventually randomized.
25% with normal renal function. 40 %
with almost normal renal function
(serum Creatinine <150 mmol/L).
Limited potential for improvement in
primary outcome limits conclusions
that can be drawn from subgroup
analyses.
Only 335 (83%) of patients randomized
to revascularization had a procedure,
with technical success in 317 (78.6%).
110 patients (13%) did not receive
randomized treatment intervention,
(86 were in the revascularization
group).
No post-procedure imaging.
Substantial renal artery stenosis not
deﬁned.
41% of patients had a stenosis of <
70%, and 59% of patients had a
stenosis of >70%.
CORAL2 Original protocol Protocol changes Patients eventually randomized
Cardiovascular Outcomes in Renal
Atherosclerotic Lesions.
Stenting and Medical therapy for Atherosclerotic
Renal Artery Stenosis.
All angiograms/imaging were analyzed by the
angiographic core laboratory, with the use of a
validated computerized quantitative vascular
analysis program.
Crossovers were assessed by a designated
crossover committee.
Hypertension with a systolic blood
pressure of >155 mmHg while
receiving two or more antihypertensive
medications.
Different thresholds of optimal blood
pressure control for diabetic or CKD
patients and non-diabetic patients,
130 mmHg vs 140 mmHg respectively.
The threshold of 155 mmHg for
deﬁning systolic hypertension was no
longer speciﬁed.
No minimum drug requirement.
25 to 30% of patients had well
controlled BP.
Approximately one-third of cohort
(311 patients) were diabetic.
1080 participants were needed for the
study to have 90% power to test the
hypothesis that stenting would reduce
the incidence of the primary end point
by 25% (hazard ratio, 0.75) at 2 years,
at a two-sided type I error rate of 0.05.
Study under recruited, data monitoring
committee terminated recruitment
after 947 participants randomized, and
follow-up was extended from January
2010 to September 2012, to preserve
the statistical power; trial was
947 patients were enrolled.
Subgroup analysis was reported.
Continued
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Table 2-continued
CORAL2 Original protocol Protocol changes Patients eventually randomized
therefore not powered for subgroup
analysis.
Embolic protection devices required. After August 2006, embolic protection
devices at operators discretion.
Severe renal artery stenosis was
deﬁned angiographically as:
stenosis of >80% but <100%; or
stenosis of >60% but <80% with a
systolic pressure gradient of at least
20 mmHg.
Severe renal- artery stenosis could be
identiﬁed with duplex ultrasonography,
MRA or CTA.
Pressure gradients not required.
Angiography only performed in 68% of
patients, and eventual degree of
stenosis was 67.3 þ 11.4% in the
stenting group and 66.9 þ 11.9% in the
medical group according to core
laboratory analysis.
In an interim analysis of 611
randomized subjects in CORAL: 7% of
patients had a renal diameter stenosis
<50%, 26% had diameter stenosis of
<60%, 29% had a 60e70% stenosis,
(i.e. 55% had <70% stenosis); 24% had
>70e80% stenosis, and 21% had a
stenosis >80%.22
Patients with ischaemic nephropathy,
and serum creatinine <354 mmol/l,
kidneys >7.0 cm in size.
Non-hypertensive patients who had
renal-artery stenosis could be enrolled
if they had CKD, (>Stage IIIA, i.e. eGFR
of <60 mls/min/1.73 m2).
Around 50% of the cohort had either
no renal failure, or were Stage I or
Stage II CKD, (i.e. eGFR of >60 mls/
min/1.73 m2).
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The Management of Renal Artery Stenosis 471major confounder in the outcome of this trial.23 A creatinine
level of 354 mmol/L equivalent to an eGFR of 12.5 mL/min/
1.73 m2 was used as a cut-off, which may be considered
signiﬁcantly elevated by many nephrologists and to be
associated with irretrievable renal damage. Also patients
with decreased eGFR were included without associated
hypertension, another group less likely to beneﬁt (see
Table 2).
A total of 5,322 patients with RAS were screened, 82%
(4375) initially assessed as suitable were not enrolled in this
study despite slow enrolment. In over 44% the reason for
non-inclusion in this trial was unspeciﬁed, perhaps creating
bias. A total of 947 patients were enrolled and randomi-
zation was slow, and as the study was under recruited
follow-up was extended from 2 to 3 years to preserve the
statistical power; this trial was therefore not powered for
subgroup analyses that were eventually reported anyway.
Of the patients 25e30% had well-controlled BP, around 50%
of the cohort had either no renal failure or were stage I or
stage II CKD, and the eGFR only just put patients (with eGFR
of 57e58 mL/min) into the stage IIIA CKD category (eGFR
45e59 mL/min). Angiography was eventually only per-
formed in 68% of patients, and the degree of stenosis was
consistently overestimated both in the stenting group and
in the medical group according to core laboratory analysis
(5.2% and 7.4%). In an interim analysis of 611 randomized
subjects in CORAL, 7% of patients had a renal diameter
stenosis <50%, 26% had diameter stenosis of <60%, 29%
had a 60e70% stenosis (i.e. 55% were less than 70% ste-
nosis), 24% had >70e80% stenosis, and 21% had a stenosis
>80%, but these data were published only in abstract form,
and not included in the ﬁnal report.22
In CORAL, at baseline, the mean number of antihyper-
tensive drugs per participant was 2.1  1.6 medications;
this increased in both groups, and did not signiﬁcantly differ
between the two groups (3.3  1.5 and 3.5  1.4 medi-
cations respectively). Systolic BP decreased in both groups
(by 15.6  25.8 mmHg) and systolic BP was only modestly
but insigniﬁcantly lower in the stent group than in the
medical therapy group (2.3 mmHg), but this difference
persisted throughout the follow-up period.
These data strongly suggest that despite an initial one-
third of patients starting off with optimal BP, medical
therapy was signiﬁcantly inadequate in two-thirds, and that
these data were not stratiﬁed for diabetic patients who
started off with different thresholds (the target level of BP
was less than 140/90 mmHg for patients without coexisting
conditions, and less than 130/80 mmHg for patients with
diabetes or CKD). Also, 33% of patients had lesions of less
than 60% (perhaps this ﬁgure is even higher because of core
laboratory discrepancies), and, conceivably in this study,
lesions that were stented that were not signiﬁcant enough
to have the effect of renal hypoperfusion, and hence no
effect on BP with revascularization. The lack of haemody-
namic PG to conﬁrm the severity of the lesions, and to
separate patients with renovascular hypertension, or to
differentiate those with atherosclerotic RAS, truncal from
ostial disease, and those with essential hypertension was asigniﬁcant drawback. In addition, it is not very clear
whether the data from patients with less that 60% stenosis
were included in the ﬁnal analysis.
The authors concluded that RA stenting did not confer a
signiﬁcant beneﬁt with respect to the prevention of clinical
events when added to comprehensive, multifactorial med-
ical therapy in people with atherosclerotic RAS and hyper-
tension or CKD. But what CORAL really demonstrated was
that patients with moderate RAS of around 67%, one-third
with less than 60% stenosis, one-third of patients with
controlled hypertension with two medications, and two-
thirds of patients with poorly controlled hypertension,
starting with suboptimal drug therapy, and 50% of patients
with stage II or less CKD, did not beneﬁt from stenting
compared with best medical therapy over 3 years. Unfor-
tunately, with this study there is an assumption that a
stenosis greater than 80%, or systolic BP > 160 mmHg do
not beneﬁt from intervention. And perhaps foremost in the
minds of vascular interventionalists, the question that this
study did not answer was: What is the inﬂuence of inter-
vention in patients with severe high grade RAS and severe
hypertension?DISCUSSION
Although the CORAL and ASTRAL trials showed negative
results, numerous single-centre trials and observational
studies have demonstrated promising results for interven-
tion. In 500 patients followed up for 10 years after surgical
RA revascularization, 85% of patients had improvement of
their hypertension with 12% cured, and 70% of the 40 pa-
tients with end-stage renal failure became dialysis inde-
pendent.24,25 Many other reports of surgical
revascularization show similar experiences, and perhaps the
role of patient selection for open revascularization pro-
cedures are much more stringent than interventional pro-
cedures, even in these major trials, and needs to be
revisited.
A systematic review of 25 prospective, observational
cohort studies, comparing the outcomes of patients after
percutaneous RA angioplasty (21 involving stents, 4 angio-
plasty only) demonstrated signiﬁcant improvement in sys-
tolic and diastolic BP.26 A further review involving 14
prospective observational cohort studies on patients
receiving renal intervention demonstrated hypertension
improvement in 69% of patients, with cure in 20%, and 49%
had RF improvement and stabilization rates of 30% and
38%, respectively.27
Perhaps the entry criteria for these trials (ASTRAL and
CORAL) were overly liberal, with ASTRAL even more so,
diluting the potential beneﬁt of such a trial, and compro-
mising future trials, with the inclusion of patients with
diabetes, two-drug hypertension, and moderate RAS. In a
model published by Modrall et al.,28 two-drug hypertension
equates to a 7% likelihood of a BP response to renal
stenting, and other outcome measures must therefore be
considered.
472 I.V. Mohan and V. BourkeConsideration in future trials must be given to functional
testing and using imaging tools such as functional MRI for
assessment of renal physiology, which is not as simplistic as
presented in these trials. As far as possible, the interven-
tional procedure must be standardized, including the use of
embolic protection devices. Consideration must also be
given to assessment of the peri-renal aorta and the pres-
ence of atheromatous disease on the aortic wall, the posi-
tion of the stenosis, i.e. truncal or ostial, the size and
condition of the contralateral kidney, renal cortical thick-
ness, and kidney size over time and progression of CKD;
there are very few data in the trial reports of ASTRAL and
CORAL to permit any analysis of the contribution of any of
these factors.
Best evidence still supports intervention for patients with
RAS of >80% with a signiﬁcant translesional PG; difﬁcult to
control BP with more than three antihypertensives, espe-
cially in younger patients; and those with truncal rather
than ostial stenosis; patients with a rapid deterioration of
RF; ﬂash pulmonary oedema; and post-transplant RAS.
Procedures must be performed in expert hands using stents
and embolic protection devices, and careful attention must
be given to those who deteriorate after intervention, to
identify which are the associated factors. ASTRAL and
CORAL, however, despite controversy, have done the
nephrology world a service, by decreasing the quantity of
“drive by” angioplasty and stenting of the renal arteries
that had been previously performed; but the role and
beneﬁt of intervention for RAS is still no clearer after these
trials.
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